1drop's 1copy COVID-19 qPCR Multi Kit Granted Emergency Use Authorization by FDA
By LabMedica International staff writers Posted on 14 May 2020 |
Image: 1copy COVID-19 qPCR Multi Kit (Photo courtesy of 1drop Inc.)
1drop Inc. (Gyeonggi-do, Korea) has secured emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the company’s 1copy COVID-19 qPCR Multi Kit.
The 1copy COVID-19 qPCR Multi Kit allows for the qualitative detection of SARS-CoV-2 by amplification of two target genes (E gene and RdRp gene) of the virus causing COVID-19 with real-time qPCR (including reverse-transcription reaction) via RNA extracted from clinical specimens (nasopharyngeal swabs or oropharyngeal swabs) of suspected respiratory infectious disease patients. RdRp is the SARS-CoV-2 specific detection target, and the E gene is detection target specific to the beta coronavirus.
In addition to its extremely high sensitivity (limit of detection of 200 copies per mL), the PCR kit has a short measurement time that allows to obtain results in less than two hours. Hospitals and reference laboratories can run the new assay on a wide range of Real-Time PCR Instruments which are widely available across the world. The 1copy COVID-19 qPCR Multi Kit is presently approved and/or commercialized in several countries, including Germany, South Korea, Sri Lanka, Luxemburg, Paraguay, Georgia, Bulgaria and Canada.
Related Links:
1drop Inc.
The 1copy COVID-19 qPCR Multi Kit allows for the qualitative detection of SARS-CoV-2 by amplification of two target genes (E gene and RdRp gene) of the virus causing COVID-19 with real-time qPCR (including reverse-transcription reaction) via RNA extracted from clinical specimens (nasopharyngeal swabs or oropharyngeal swabs) of suspected respiratory infectious disease patients. RdRp is the SARS-CoV-2 specific detection target, and the E gene is detection target specific to the beta coronavirus.
In addition to its extremely high sensitivity (limit of detection of 200 copies per mL), the PCR kit has a short measurement time that allows to obtain results in less than two hours. Hospitals and reference laboratories can run the new assay on a wide range of Real-Time PCR Instruments which are widely available across the world. The 1copy COVID-19 qPCR Multi Kit is presently approved and/or commercialized in several countries, including Germany, South Korea, Sri Lanka, Luxemburg, Paraguay, Georgia, Bulgaria and Canada.
Related Links:
1drop Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants